Answers are grounded in this paper and cite their sources.
Tumor-infiltrating CD8 + T cells are a key determinant of anti-tumor efficacy in immunotherapy.IL-7 has been explored as a cytokine therapy to expand CD8 + T cells, showing promising anti-tumor effects in preclinical models.However, clinical outcomes remain limited, likely due to the immunosuppressive tumor microenvironment.To enhance the efficacy of IL-7 therapy, we reanalyzed publicly available single-cell RNA-sequencing (scRNA-seq) data of tumors treated with IL-7, identifying elevated TGF- signaling in CD8 + T cells following treatment.As TGF- impairs CD8 + T cell function and antagonizes IL-7 signaling, we developed a bifunctional fusion protein, recombinant human IL-7 (rhIL-7)-hyFc-sTBRII (IL7-TBRII), by fusing a TGF- trap (Fc-TBRII) to rhIL-7-hyFc (IL7-Fc).We evaluated the binding affinities and functionalities of each domain in vitro and in vivo, and assessed anti-tumor effects in the MC38 colon cancer model.IL7-TBRII demonstrated superior anti-tumor efficacy compared to IL7-Fc or Fc-TBRII alone, primarily through increased infiltration of cytotoxic CD8 + T cells into tumors.Also, IL7-TBRII expanded the number of activated CD44 + CD8 + T cells.Furthermore, IL7-TBRII reduced metastasis in the 4T1 breast cancer model by reshaping the immune cell composition, and demonstrated synergistic efficacy when combined with radiotherapy or anti-CTLA-4 therapy in the EMT6 breast tumor model.These findings suggest that dual modulation of the IL-7 and TGF- pathways by IL7-TBRII effectively reprograms the immune microenvironment in both primary and metastatic tumors, particularly by promoting CD8 + T cell activation and infiltration, thus offering a promising strategy to improve clinical responses to immunotherapy.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: